Vigil moves into Phase II with Alzheimer's pill

24 January 2025

Vigil Neuroscience (Nasdaq: VIGL) has announced plans to advance its oral TREM2 agonist, VG-3927, into Phase II trials for Alzheimer’s disease this year.

The decision follows positive data from a completed Phase I trial, which demonstrated a favorable safety profile and a "robust and dose-dependent" reduction of a key target.

The company is moving forward following the removal of a partial clinical hold by the US regulator in 2024, with plans to initiate mid-stage research in the third quarter of 2025.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK